UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 13, 2023

Eloxx Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-31326**	**84-1368850**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

480 Arsenal Way, Suite 130, Watertown, MA	**02451**
(Address of principal executive offices)	**(Zip Code)**

(Registrant's telephone number, including area code): (781) 577-5300

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value per share	ELOX	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously announced, on June 27, 2023, Eloxx Pharmaceuticals, Inc. (the "Company") hosted an investor and analyst call ("KOL Day") featuring key opinion leaders to review insights on Alport syndrome and to review the Company's additional data from its ELX-02 Phase 2 clinical trial for the potential treatment of Alport syndrome. Select slides included in the presentation materials used at the KOL Day are filed as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Slides from KOL Day, dated June 27, 2023.
104	Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 13, 2023

ELOXX PHARMACEUTICALS, INC.

By: /s/ Sumit Aggarwal
Name: Sumit Aggarwal
Title: President and Chief Executive Officer

Patients had autosomal recessive disease with differing levels of background RAAS blockade

Baseline characteristics of patients that have completed therapy

Patient	Age	Sex	COl4 Gene Affected	Nonsense Mutation	RAAS Block dose	Cr (mg/dL)	Proteinuria (mg/g)
4401-01	13	Male	*COL4A4*	**c.2906C>G*; p.Ser969X**	Enalapril 2.5 mg QD	0.7	1299
4401-02	13	Male	*COL4A4*	**c.2906C>G*; p.Ser969X**	Enalapril 32.5 mg QD	0.5	1646
4402-01	19	Female	*COL4A4*	**c.2906C>G*; p.Ser969X**	Enalapril 5 mg QD	1.31	1645

*Most common mutation in the UK

Eloxx PHARMACEUTICALS

Remission in one Alport patient with an approx. 50% reduction from baseline

Phase 2 Alport patient results to date



Patient 4401-02 achieved partial remission after completing 8 weeks of treatment

- Average reduction of baseline ~50%
- 5 out of 8 UPCR readings were on average 53% below baseline

* UPCR averaged over 6 values collected in 8 weeks for 4401-01 and 4401-02. UPCR values collected for 4401-01 and 4401-02 at week 6 were excluded as they were deemed to be unreliable due to inconsistent processing during Easter holidays and inconsistency with the clinical presentation. All 8 UPCR values included for 4401-02

Eloxx PHARMACEUTICALS

Rapid remission in Patient 4401-02 with rebound 1 month after withdrawing treatment very encouraging

Proteinuria (UPCR) change in patient 4401-02



* UPCR averaged over 6 values collected in 8 weeks. UPCR values collected at week 6 were excluded as they were deemed to be unreliable due to inconsistent processing during Easter holidays and inconsistency with the clinical presentation

No change in other 2 patients after ELX-02 treatment

Proteinuria change in patient 4401-01 and 4402-01

Patient 4401-01 UPCR change over treatment



Patient 4402-01 UPCR change over treatment